telephone and FAX numbers, and any specific questions they want addressed at the workshops to the contact person listed above. There is no registration fee for these workshops, but advance registration is required. Interested persons are encouraged to register early because seating is limited to 100 registrants.

SUPPLEMENTARY INFORMATION: The purpose of these workshops is to provide training and dialogue among the medical gas industry, local, State, and Federal Government agencies. The workshops will provide a forum to discuss the regulation of the compressed gas industry, convey knowledge about FDA's operations and policies, and explain the requirements for compliance with CGMP regulations. The workshops will also provide a segment on enforcement procedures used by FDA.

Dated: April 11, 1996.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 96–9484 Filed 4–17–96; 8:45 am]

BILLING CODE 4160–01–F

Health Care Financing Administration

Agency Information Collection Activities: Proposed Collection; Comment Request

AGENCY: Health Care Financing Administration, HHS.

In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Health Care Financing Administration (HCFA), Department of Health and Human Services, is publishing the following summaries of proposed collections for public comment. Interested persons are invited to send comments regarding the burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

1. *Type of Information Collection Request:* Extension of a currently approved collection; *Title of Information Collection:* Medicare Participating Physician or Supplier Agreement, HCFA 460; *Form No.:* HCFA 460; *Use:* The HCFA 460 is completed by nonparticipating physicians and suppliers if they choose to participate in Medicare Part B. By signing the agreement, the physician or supplier agrees to take assignment on all Medicare claims. To take assignment means to accept the Medicare allowed amount as payment in full for the services they furnish and to charge the beneficiary no more than the deductible and coinsurance for the covered service. In exchange for signing the agreement, the physician or supplier receives a significant number of program benefits not available to nonparticipating physicians and suppliers. The information is needed to know to whom to provide these benefits. *Frequency:* Once, unless re-enrolled; *Affected Public:* Individuals or Households, and Business or other for-profit; *Number of Respondents:* 70,000; *Total Annual Responses:* 70,000; *Total Annual Hours Requested:* 17,500.

2. *Type of Information Collection Request:* Extension of a currently approved collection; *Title of Information Collection:* Hospital Conditions of Participation—42 CFR Part 482; *Form No.:* HCFA–R–48; *Use:* Hospitals seeking to participate in the Medicare and Medicaid programs must meet the Conditions of Participation (COP) for Hospitals, 42 CFR Part 482. The information collection requirements contained in this package are needed to implement the Medicare and Medicaid COP for hospitals. *Frequency:* Annually; *Affected Public:* Not-for-profit institutions, Federal Government, and State, Local or Tribal Government; *Number of Respondents:* 6,700; *Total Annual Responses:* 6,700; *Total Annual Hours Requested:* 62,657.

To request copies of the proposed paperwork collections referenced above, call the Reports Clearance Office on (410) 786–1326. Written comments and recommendations for the proposed information collections should be sent within 60 days of this notice directly to the HCFA Paperwork Clearance Officer designated at the following address: HCFA, Office of Financial and Human Resources, Management Planning and Analysis Staff, Attention: Louis Blank, Room C2–26–17, 7500 Security Boulevard, Baltimore, Maryland 21244–1850.

Dated: April 12, 1996.

Kathleen B. Larson,

Director, Management Planning and Analysis Staff, Office of Financial and Human Resources.

[FR Doc. 96–9536 Filed 4–17–96; 8:45 am]

BILLING CODE 4120–03–P

Health Resources and Services Administration

The Ryan White Comprehensive Aids Resources Emergency Act of 1990; Availability of Funds for Early Intervention Services

AGENCY: Health Resources and Services Administration.

ACTION: Notice of extension of application due date.

SUMMARY: This notice extends the due date previously published in the Federal Register on March 20, 1996 (61 FR 11424) for applications for discretionary grants to provide outpatient early intervention services including primary care services with respect to human immunodeficiency virus (HIV) disease. The new due date is June 12, 1996. All other information remains unchanged.

Dated: April 12, 1996.

Ciro V. Sumaya,

Administrator.

[FR Doc. 96–9542 Filed 4–17–96; 8:45 am]

BILLING CODE 4160–15–P

Availability of Funds for the National Health Service Corps Loan Repayment Program and Grants for State Loan Repayment Programs

AGENCY: Health Resources and Services Administration, DHHS.

ACTION: Correction of telephone number.

SUMMARY: The following correction should be made to the notice published in the Federal Register on Thursday, March 28, 1996 (61 FR 13861):

On page 13861 in the second column, last paragraph, the telephone number to receive application materials for awards should be (703) 821–8955. The toll-free number remains 1–800–221–9393.

All other information remains unchanged.

Dated: April 12, 1996.

Ciro V. Sumaya,

Administrator.

[FR Doc. 96–9541 Filed 4–17–96; 8:45 am]

BILLING CODE 4160–15–P

National Institutes of Health

Submission for OMB Review; Comment Request; Familial Cancer and the BRCA1 Gene in the Jewish Community of Greater Washington

SUMMARY: Under the provisions of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the National Cancer Institute (NCI), the National

Institutes of Health (NIH), has submitted to the Office of Management and Budget (OMB) a request to review and approve the information collection listed below. This proposed information collection was previously published in the Federal Register on November 3, 1995, page 55845 and allowed 60 days for public comment. One public comment was received, requesting a copy of the NIH approved study protocol. The purpose of this notice is to allow an additional 30 days for public comment. The National Institutes of Health may not conduct or sponsor, and the respondent is not required to respond to, an information collection that has been extended, revised, or implemented on or after October 1, 1995, unless it displays a currently valid OMB control number.

PROPOSED COLLECTION: Title: Familial Cancer and the BRCA1 Gene in the Jewish Community of Greater Washington. Type of Information Collection Request: EXTENSION. Need and Use of Information Collection: This research study will determine how common a particular alteration in the BRCA1 gene occurs in Jewish individuals, and what the risk of cancer is in individuals who carry this alteration. With the assistance of Jewish community leaders in the Washington, D.C. area, Jewish volunteers will be recruited for the study. Volunteers will donate a small blood sample and complete a self-administered questionnaire. The questionnaire will include a brief personal medical history, and a detailed family history of cancer. Participants will be notified of the overall study results, which may include recommendations about genetic testing and the availability of testing programs. Frequency of Response: One-time. Affected Public: Individuals. Type of Respondents: Jewish adult volunteers. The annual reporting burden is as follows: Estimated Number of Respondents: 7,700; Estimated Number of Responses per Respondent: 1; Average Burden Hours per Respondent: .50; and Estimated Total Annual Burden Hours Requested: 3850. The annualized cost to respondents is estimated at: $38,500. There are no Capital Costs to report. There are no Operating or Maintenance Costs to report.

REQUEST FOR COMMENTS: Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (2) The accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) Ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

DIRECT COMMENTS TO OMB: Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the: Office of Management and Budget, Office of Regulatory Affairs, New Executive Office Building, Room 10235, Washington, D.C. 20503, Attention: Desk Officer for NIH. To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact: Dr. Jeffery P. Struewing, Principal Investigator, Genetic Epidemiology Branch, NCI, NIH, Building EPN Room 439, 6130 Executive Blvd MSC 7372, Bethesda, MD 20892–7372, or call non-toll-free number (301) 496–4375 or E-mail your request, including your address to: struewing@nih.gov.

COMMENTS DUE DATE: Comments regarding this information collection are best assured of having their full effect if received within 30-days of the date of this publication.

Dated: April 1, 1996.

Philip D. Amoruso,

NCI Executive Officer.

[FR Doc. 96–9526 Filed 4–17–96; 8:45 am]

BILLING CODE 4140–01–M

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health.

ACTION: Notice.

The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for U.S. companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804 (telephone 301/496–7057; fax 301/402–0220). A signed Confidential Disclosure Agreement (CDA) will be required to receive copies of the patent applications.

Dimeric Arylisoquinoline Alkaloids and Synthesis Methods Thereof

Bringmann, G., Boyd, M.R., Gotz, R., Kelly, T.R. (NCI)

Filed 23 Dec 94

Serial No. 08/363,684

Licensing Contact: Gloria Richmond, 301/496–7056 ext 268

The present invention relates to a new method of chemical synthesis of known and new dimeric arylisoquinoline alkaloids. These compounds are members of a general class known as naphthylisoquinoline alkaloids. These dimeric alkaloids have been found to be effective inhibitors of HIV replication in human immune cells. The method of this invention provides access not only to known but also heretofore unknown medically useful compounds. The invention also provides for new dimeric arylisoquinoline compounds and derivatives thereof. (portfolio: Infectious Diseases—Therapeutics, antivirals, AIDS)

Dimeric Naphthylisoquinoline Alkaloids and Synthesis Methods Thereof

Bringmann, G., Harmsen, S., Boyd, M.R. (NCI)

Filed 22 July 94

Serial No. 08/279,339

Licensing Contact: Gloria Richmond, 301/496–7056 ext 268

This invention embodies the synthesis of homodimeric and heterodimeric naphthylisoquinoline alkaloids and derivatives. The methods presented in the invention are advantageous because they permit, for the first time, the *in vitro* synthesis of compounds for which the only known natural source is the rare tropical vine, *Ancistrocladus korupensis* of Central Africa. This class of compounds has been demonstrated to be effective in inhibiting the ability of HIV to replicate and infect cells. Therefore, the dimeric alkaloids appear to comprise a novel class of antiviral drugs that may be very useful by themselves or in combination with other treatments. (portfolio: Infectious Diseases—Therapeutics, antivirals, AIDS)